St Jude Medical News

's stock had its "buy" rating restated by equities researchers at TheStreet in a report issued on Thursday, AnalystRatingsNetwork reports.

ST. PAUL, Minn. & PARIS -- -- St. Jude Medical, Inc. , a global medical device company, today announced that the company's EnligHTN Multi-Electrode Renal Denervation System provides a safe, rapid and sustained reduction in blood pressure measurements after one year.

Bargains are getting harder and harder to find in the med-tech sector these days, and with Medtronic sporting a double-digit EV/EBITDA ratio and a 35% gain in the share price over the last year, it doesn't necessarily jump out as a bargain.

ST. PAUL, Minn. & PARIS -- -- St. Jude Medical, Inc. , a global medical device company, today announced the start of its landmark EnligHTNment clinical study.

's stock had its "neutral" rating reaffirmed by research analysts at Goldman Sachs in a report released on Monday, AnalystRatingsNetwork.com reports.

StockCall.com Provides Stock Research on St. Jude Medical Inc., Hologic Inc., Navidea Biopharmaceuticals Inc., Edwards Lifesciences Corp., and ResMed Inc.

The chorale will be performing selections from grand opera choruses, followed by selections from "The Wizard of Oz," "The Wiz," "Wicked" and other popular songs from the days of MGM and Cole Porter.

St. Jude Medical, Inc. announced enrollment of the first patient in the EnligHTN III trial.

's stock had its "overweight" rating reaffirmed by Barclays Capital in a research note issued on Thursday, Analyst Ratings.Net reports.

After years of safety worries about heart pacing leads, the sun could be appearing through the clouds for St.

St. Jude Medical won FDA clearance for its Ellipse and Assura lines of implantable cardiac devices.

Renal denervation therapy is a new, minimally invasive procedure that will help people with hopelessly high blood pressure that just refuses to budge to medication.

Today, the economic data was good, but apparently not good enough to sustain the market from its first down day in a week.

's stock had its "neutral" rating restated by Zacks in a report issued on Thursday, Stock Ratings Network.com reports.

St. Jude Medical Inc.'s Durata lead, the wire used to connect life-saving defibrillators to the heart, proved safe and reliable in an independent review that should ease concerns about its use, researchers said.

The Global Atherectomy and Thrombectomy Devices market has also been witnessing an increase in patent grants and US FDA approvals.

Nanostim Inc.'s miniaturized pacemaker, a device the size of a AAA battery placed entirely in the heart, appeared promising in its first human trials.

Every once in a while I am amazed at how some companies apparently can do no wrong, despite a constant stream of negative news.

's stock had its "buy" rating restated by equities researchers at Oriel Securities Ltd in a report issued on Wednesday, Stock Ratings Network reports.

's stock had its "market perform" rating restated by analysts at BMO Capital Markets in a research report issued to clients and investors on Friday, Stock Ratings Network reports.